Enteral nutrition emulsion and preparation method thereof

By modifying astaxanthin and vitamin E derivatives, the water solubility and stability problems in enteral nutrition emulsions are solved, and the effect of improving immunity and antioxidant performance is achieved, and the integration of enteral nutrition emulsions is improved. Performance and stability.

CN119054914AInactive Publication Date: 2024-12-03FUJIRO (XIAMEN) PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411341913.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-25
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

As a strongly oxidative carotenoid, astaxanthin has limited ability to quench and capture active free radicals in aqueous solution, which limits its effective utilization and stability in enteral nutritional emulsions. , and is easily oxidized and degraded.

Method used

By modifying astaxanthin with vitamin E derivatives with good hydrophilicity, it improves its water solubility and stability, forming modified astaxanthin derivatives, and adding them to enteral nutritional emulsions to enhance immunity and Antioxidant properties.

Benefits of technology

Modified astaxanthin improves patients' immunity in enteral nutritional emulsions, enhances antioxidant ability, prevents oils from deteriorating, and improves the comprehensive performance and stability of the emulsions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005059945450000071
    Figure BDA0005059945450000071
  • Figure BDA0005059945450000081
    Figure BDA0005059945450000081
  • Figure BDA0005059945450000091
    Figure BDA0005059945450000091
Patent Text Reader

Abstract

The invention relates to the technical field of medical, dental or dressing preparations, in particular to an enteral nutrition emulsion and a preparation method thereof. The enteral nutrition emulsion is prepared from the following components in parts by weight: 13 to 23 parts of soybean protein peptide powder, 10 to 20 parts of whey protein isolate powder, 6 to 12 parts of fat, 0.5 to 2 parts of arginine, 3 to 8 parts of lecithin, 12 to 20 parts of dietary fiber, 5 to 10 parts of oligosaccharide, 0.2 to 1 part of mineral substance, 0.1 to 0.3 part of vitamin, 0.1 to 0.3 part of emulsifier, 0.001 to 0.005 part of modified astaxanthin and 50 to 80 parts of water. The invention also provides a preparation method of the composition. Compared with the prior art, the enteral nutrition emulsion prepared by the invention is stable in character and easy to absorb, and not only can meet daily nutrition of patients, but also can improve immunity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of medical, dental or cosmetic preparations, and in particular to an enteral nutrition emulsion and a preparation method thereof. Background Art

[0002] Enteral nutrition emulsion is a special medical nutrition product, mainly used for patients who cannot get enough nutrition through normal diet for various reasons. Enteral nutrition emulsion contains a variety of nutrients such as protein, fat, carbohydrates, dietary fiber, vitamins and minerals, which can provide comprehensive nutritional support. It is usually a light gray-yellow to light brown milky liquid, which may contain solid suspension. It provides all the nutrition needed for patients who cannot eat normally, or as a nutritional supplement. It is suitable for patients in high-catabolism state and recovery period to help them restore their physical strength and promote wound healing. It is suitable for patients with limited fluid intake (such as patients with heart failure), cachexia, anorexia, chewing or swallowing difficulties, and preoperative preparation for malnourished patients. The dietary fiber contained is beneficial to maintain the intestinal structure and function of patients, and is suitable for long-term application. According to the patient's energy needs, enteral nutrition emulsion can provide different levels of energy to meet the patient's daily needs.

[0003] CN201410351455.8 provides a short peptide immune-enhancing enteral nutrition emulsion and a preparation method thereof. The emulsion is obtained by a mixed concentration method from maltodextrin, isolated whey protein powder, rapeseed oil, high oleic sunflower oil, golden thread jujube extract, wolfberry extract, papaya extract, kudzu root extract, Poria extract, mulberry extract, dandelion extract, dietary fiber, minerals, vitamins, L-carnitine and taurine, emulsifier citric acid fatty acid glyceride and purified water. The emulsion can effectively improve the body's immune function and provide nutritional support for cancer patients through the synergistic effect of high-content high-quality protein peptides and the biologically active ingredients in various food ingredients that are both medicinal and edible. The preparation method is simple and suitable for the needs of large-scale industrial production.

[0004] CN201810495868.1 provides an astaxanthin enteral nutrition emulsion, a dry emulsion, and a preparation method and application thereof, which belongs to the field of food production. The astaxanthin enteral nutrition emulsion includes 1% to 5% hydroxypropyl methylcellulose, 1% to 3% maltodextrin, 1% to 4% corn oil, 0.002% to 0.006% astaxanthin oil and 89% to 96% water by mass percentage. The astaxanthin enteral nutrition emulsion provided by the invention has stable properties, good taste, rapid absorption, easy digestion and absorption, and can meet the daily nutritional needs of users. The astaxanthin component is beneficial to the self-repair and immunity enhancement of the user's body. It can be used as a common food for normal people or weak people to eat, and can also be used as a nutritional preparation for clinical enteral nutrition support for patients with gastrointestinal dysfunction. It can also be used as a nutritional support preparation for ordinary patients to supplement the more comprehensive nutrition and functional components required for daily life.

[0005] Enteral nutrition emulsions contain fats and unsaturated fatty acids, which are susceptible to oxidation, leading to product deterioration and loss of nutrients. The appropriate addition of antioxidants helps ensure that patients consume safe and healthy nutritional preparations, provided that food safety standards are met. Considering the special conditions of patients, such as liver or kidney dysfunction, specially designed products are needed to reduce the burden on these organs. Summary of the invention

[0006] In view of the above-mentioned defects in the prior art, the technical problem to be solved by the present invention is to provide an enteral nutrition emulsion and a preparation method thereof.

[0007] Astaxanthin (3,3'-dihydroxy-4,4'-diketo-β,β'-carotene) is a keto-carotenoid. The long conjugated double bond chain of astaxanthin, the hydroxyl group and unsaturated ketone group on the terminal ring structure, and the α-hydroxyketone formed by the hydroxyl group and ketone group are the main reasons for astaxanthin's various biological functions [1]. Studies have shown that astaxanthin's ability to quench singlet oxygen and capture free radicals is more than 10 times that of β-carotene. Astaxanthin has a strong antioxidant capacity and can effectively scavenge free radicals and reduce the damage of oxidative stress to the patient's intestinal cells. Astaxanthin can also enhance the body's immune ability, improve the function of immune organs, and enhance resistance to harsh environments. It also participates in the body's cellular immunity and regulates the structure of intestinal flora by enhancing T cell function, increasing the number of neutrophils and natural killer cells, and improving host lipid metabolism. It has a regulatory effect on intestinal flora disorders induced by a high-fat diet. Therefore, adding it to the enteral nutrition emulsion can not only play an antioxidant and anti-deterioration role, but also can improve the patient's immunity and improve the intestinal environment, etc., but astaxanthin, as a carotenoid with strong oxidizing properties, is a lipophilic compound, which limits its quenching of singlet oxygen in aqueous solution, directly captures active free radicals, and inhibits lipid peroxidation, etc., and at the same time, it also limits the transportation of astaxanthin in animals and its combination with proteins in the body, inhibiting the effective utilization of astaxanthin. Moreover, due to the strong antioxidant properties of astaxanthin, astaxanthin is easily oxidized and degraded. Therefore, the present invention provides a modified astaxanthin, which is modified by a vitamin E derivative with good hydrophilicity to obtain a better water-soluble astaxanthin derivative, and the vitamin E derivative structure also contains a vitamin E structure with antioxidant effect, so it is conducive to improving the stability of the modified astaxanthin. Since the water solubility and stability of the modified astaxanthin are improved, adding modified astaxanthin to enteral nutrition emulsions can not only enhance the patient's immunity, but also act as an antioxidant to prevent the oil and fat therein from deteriorating, thereby improving the overall performance and stability of the enteral nutrition emulsion.

[0008] To achieve the above-mentioned purpose, the present invention provides an enteral nutrition emulsion, comprising the following components in parts by weight: 13 to 23 parts of soy protein peptide powder, 10 to 20 parts of isolated whey protein powder, 6 to 12 parts of fat, 0.5 to 2 parts of arginine, 3 to 8 parts of lecithin, 12 to 20 parts of dietary fiber, 5 to 10 parts of oligosaccharides, 0.2 to 1 part of minerals, 0.1 to 0.3 parts of vitamins, 0.1 to 0.3 parts of emulsifiers, 0.001 to 0.005 parts of modified astaxanthin and 50 to 80 parts of water.

[0009] Furthermore, the fat is a mixture of sunflower oil, fish oil and rapeseed oil.

[0010] Furthermore, the weight ratio of sunflower oil, fish oil and rapeseed oil in the fat is 30-50:4-6:5-20.

[0011] Furthermore, the mineral is a mixture of calcium carbonate, sodium caseinate, potassium chloride, sodium chloride, ferric pyrophosphate, zinc sulfate, copper sulfate, manganese chloride, sodium molybdate, sodium selenite, potassium iodide, chromium chloride, and sodium fluoride.

[0012] Furthermore, in terms of content, the weight ratio of calcium, phosphorus, potassium, sodium, chlorine, iron, zinc, copper, manganese, molybdenum, selenium, iodine, chromium and fluorine in the minerals is 40:25:60:25:45:8.5:6.2:45:15:5:15:40:5:0.35.

[0013] Furthermore, the vitamins are vitamin A, vitamin D, vitamin E, vitamin K1, vitamin B1, vitamin B2, vitamin B6, vitamin B 12 , a mixture of niacin, folic acid, choline and biotin.

[0014] Furthermore, the vitamins A, D, E, K1, B1, B2, B6, B 12 , niacin, folic acid, choline and biotin have a weight ratio of 450:8:8:50:355:800:450:1.5:300:160:50:15.

[0015] The preparation method of the modified astaxanthin comprises the following steps:

[0016] X1. Add vitamin E polyethylene glycol succinate, maleic anhydride and 4-dimethylaminopyridine to dichloromethane, stir for 20-30 hours under nitrogen atmosphere, then add to cold ether. A precipitate will appear. Filter and dialyze with ethanol-water solution for 2-3 days, then dry for the next step.

[0017] X2. Add astaxanthin to acetone, then add the product of the previous step, 4-dimethylaminopyridine and dicyclohexylcarbodiimide. Stir for 20 to 30 hours under a nitrogen atmosphere and then add to cold ether. A precipitate will appear. Wash it three times and dialyze it for 2 to 3 days to remove impurities to obtain modified astaxanthin.

[0018] Furthermore, the molar ratio of the vitamin E polyethylene glycol succinate to maleic anhydride and 4-dimethylaminopyridine is 1:2 to 3:1.

[0019] Furthermore, the molar ratio of astaxanthin to the product of the previous step, 4-dimethylaminopyridine and dicyclohexylcarbodiimide is 1:2-2.5:1-1.5:1-1.5.

[0020] Preferably, the method for preparing the modified astaxanthin comprises the following steps:

[0021] X1. Add vitamin E polyethylene glycol succinate, maleic anhydride and 4-dimethylaminopyridine to dichloromethane in a molar ratio of 1:2 to 3:1. Stir for 20 to 30 hours under a nitrogen atmosphere and then add to cold ether. A precipitate will appear. After filtering, dialyze with ethanol aqueous solution for 2 to 3 days and then dry for the next step.

[0022] X2. Add astaxanthin to acetone, and then add the product of the previous step, 4-dimethylaminopyridine, and dicyclohexylcarbodiimide. The molar ratio of astaxanthin to the product of the previous step, 4-dimethylaminopyridine, and dicyclohexylcarbodiimide is 1:2~2.5:1~1.5:1~1.5. After stirring for 20~30 hours under a nitrogen atmosphere, add to cold ether. A precipitate will appear. After washing 3 times, dialyze for 2~3 days to remove impurities to obtain modified astaxanthin.

[0023] A method for preparing an enteral nutrition emulsion comprises the following steps:

[0024] S1. Add soy protein peptide powder, isolated whey protein powder, arginine, dietary fiber and oligosaccharides into water according to the formula, and mix and stir at 40-55° C. to obtain an aqueous phase;

[0025] S2, mixing fat and lecithin, and stirring evenly to obtain an oil phase;

[0026] S3. After mixing the water phase, the oil phase and the emulsifier, add the vitamins, minerals and the modified astaxanthin, stir evenly and homogenize, sterilize after filling, and then package.

[0027] Beneficial effects of the present invention:

[0028] 1. Compared with the prior art, the enteral nutrition emulsion prepared by the present invention has stable properties and is easy to absorb. It can not only meet the daily nutrition of patients, but also enhance immunity.

[0029] 2. The present invention improves the water solubility and stability of astaxanthin by modifying it. Adding modified astaxanthin to the enteral nutrition emulsion can not only enhance the immunity of the patient, but also act as an antioxidant to prevent the oil and fat therein from deteriorating, thereby improving the comprehensive performance and stability of the enteral nutrition emulsion. DETAILED DESCRIPTION

[0030] Polyethylene glycol, PEG500, food grade.

[0031] Example 1

[0032] A method for preparing an enteral nutrition emulsion comprises the following steps, measured in parts by weight:

[0033] S1, adding 20 parts of soy protein peptide powder, 15 parts of isolated whey protein powder, 1.5 parts of arginine, 18 parts of wheat dietary fiber, and 8 parts of oligomannan to 65 parts of water, and mixing and stirring at 50° C. to obtain an aqueous phase;

[0034] S2, mix 4 parts of sunflower oil, 0.5 parts of fish oil, 2 parts of rapeseed oil and 8 parts of soybean lecithin, and stir to obtain an oil phase;

[0035] S3, after mixing the water phase, the oil phase and 0.3 parts of citric acid fatty acid glyceride, adding 0.2 parts of vitamins, 0.5 parts of minerals and 0.003 parts of modified astaxanthin, stirring evenly and homogenizing, sterilizing after filling, and packaging;

[0036] The mineral is a mixture of calcium carbonate, sodium caseinate, potassium chloride, sodium chloride, ferric pyrophosphate, zinc sulfate, copper sulfate, manganese chloride, sodium molybdate, sodium selenite, potassium iodide, chromium chloride and sodium fluoride, and the weight ratio of calcium, phosphorus, potassium, sodium, chlorine, iron, zinc, copper, manganese, molybdenum, selenium, iodine and chromium in the mineral is 40:25:60:25:45:8.5:6.2:45:15:5:15:40:5:0.35 in terms of content;

[0037] The vitamins are vitamin A, vitamin D, vitamin E, vitamin K1, vitamin B1, vitamin B2, vitamin B6, vitamin B 12 , niacin, folic acid, choline, biotin mixture, vitamin A, vitamin D, vitamin E, vitamin K1, vitamin B1, vitamin B2, vitamin B6, vitamin B 12 , niacin, folic acid, choline and biotin have a weight ratio of 450:8:8:50:355:800:450:1.5:300:160:50:15.

[0038] The preparation method of the modified astaxanthin comprises the following steps:

[0039] X1. Add 9 g of vitamin E polyethylene glycol succinate, 0.57 g of maleic anhydride and 0.72 g of 4-dimethylaminopyridine to 100 mL of dichloromethane, stir for 24 h under nitrogen atmosphere and then add to cold ether. A precipitate will appear. Filter and dialyze against ethanol-water solution for 3 days and then dry for the next step.

[0040] X2. Add 0.6 g of astaxanthin to 30 mL of acetone, and then add 3 g of the product of the previous step, 0.12 g of 4-dimethylaminopyridine, and 0.2 g of dicyclohexylcarbodiimide. Stir for 24 h under a nitrogen atmosphere and then add to cold ether. A precipitate will appear. Wash it three times and dialyze it for 3 days to remove impurities to obtain modified astaxanthin.

[0041] Example 2

[0042] It is basically the same as Example 1, the only difference being that the modified astaxanthin is 0.001 parts.

[0043] Example 3

[0044] It is basically the same as Example 1, the only difference being that the amount of modified astaxanthin is 0.005 parts.

[0045] Comparative Example 1

[0046] It is basically the same as Example 1, the only difference being that modified astaxanthin is not added.

[0047] Comparative Example 2

[0048] It is basically the same as Example 1, the only difference being that the modified astaxanthin is replaced by astaxanthin.

[0049] Comparative Example 3

[0050] The method is basically the same as Example 1, except that the preparation method of the modified astaxanthin is different, and includes the following steps:

[0051] Add 0.6 g of astaxanthin to 30 mL of acetone, then add 0.3 g of maleic anhydride, stir for 24 h under a nitrogen atmosphere at 30 ° C, then add to cold ether, filter, collect the precipitate, dialyze for 3 days, add it together with 12 g of polyethylene glycol to dichloromethane, heat to 35 ° C, stir for 20 h, remove the solvent, and dialyze to remove impurities to obtain the product.

[0052] Test Example 1

[0053] 140 ICR mice weighing (18±2) g were taken, and 0.2 mL of tumor cell suspension was subcutaneously inoculated in the right axilla of each mouse. After 24 hours of model establishment, the mice were randomly divided into 7 groups, each with 20 mice, half of which were male and half were female. The experiment set up a control group, which was gavaged with physiological saline, and an experimental group was gavaged with the enteral nutrition emulsion of the present invention (0.05 g / mL). The mice were weighed before and after the experiment and the average value was recorded. The effect of the enteral nutrition emulsion of the present invention on the humoral immune function of tumor-bearing mice was determined by serum hemolysin determination. On the 7th day after the administration of the nutrition emulsion to each group, 0.2 mL / (20%) of sheep red blood cells were injected into the peritoneal cavity of each group of mice for primary immunization. One hour after the last administration, blood was collected, serum was separated, and the half hemolysis value HC was determined and calculated. 50 .

[0054] Table 1 Effects of enteral nutrition emulsion on immune function

[0055]

[0056] The serum hemolysin assay is an experimental method for evaluating the humoral immune function of mice. By this method, the content of hemolysin in mouse serum can be determined, thereby reflecting the humoral immune ability of mice. In the tumor-bearing mouse model, the humoral immune function may be affected by the tumor burden, and the appropriate increase in the serum hemolysin level may be associated with better humoral immune function. From the test results, it can be seen that the enteral nutrition emulsion prepared by the present invention has a certain weight gain effect on tumor-bearing mice, which shows that the emulsion prepared by the present invention can provide comprehensive nutritional support, and nutritional supplementation is crucial for immunity. Compared with the control example 1, the serum hemolysin level in Example 1 is higher, which may be because astaxanthin itself has the ability to enhance the body's immune ability, improve the function of immune organs, enhance resistance to harsh environments, and participate in the body's cellular immunity by enhancing T cell function, increasing the number of neutrophils and natural killer cells, etc., so the immune function level of the tumor-bearing mice in Example 1 is better. Although astaxanthin was also added in Control Example 2, it has extremely poor water solubility and is unstable, which may affect its function in the enteral nutrition emulsion. Control Example 3 also modified astaxanthin to enhance its water solubility and stability, so the performance is better than that of Control Example 2. Compared with Examples 1 to 3, the amount of modified astaxanthin is more different. From the experimental results, Example 1 performs best.

[0057] Test Example 2

[0058] The enteral nutrition emulsion prepared by the present invention was subjected to a stability test. The prepared sample was placed at 40° C. for a 6-month accelerated viscosity tracking test. The viscosity of the emulsion before and after the start was tested using a viscometer, and the properties of the emulsion before and after were observed and recorded.

[0059] Table 2 Stability test of enteral nutrition emulsion

[0060]

[0061]

[0062] From the stability test results, it can be seen that the enteral nutrition emulsion in the embodiment has the best stability, while the enteral nutrition emulsion in the reference example has changed to varying degrees over time. Compared with the embodiment, the reference example 1 does not add modified astaxanthin, and the enteral nutrition emulsion contains fat and unsaturated fatty acids, which are easily oxidized, resulting in product deterioration and changes in properties. Astaxanthin, as a strong antioxidant, can resist oxidation well and play a role in preventing deterioration, so the enteral nutrition emulsion in the embodiment has better stability. However, astaxanthin itself has poor water solubility and stability, which also affects its antioxidant effect to a certain extent, so the stability of the enteral nutrition emulsion in reference example 2 is not as good as that in embodiment 1. In reference example 3, astaxanthin is also modified, but compared with the vitamin E derivative used in embodiment 1 for modification, the polyethylene glycol used in embodiment 2 does not have antioxidant properties, and the vitamin E derivative structure also contains a vitamin E structure with antioxidant effect, so it is conducive to further improving the stability and antioxidant properties of modified astaxanthin. Since the water solubility and stability of the modified astaxanthin are improved, adding modified astaxanthin to enteral nutrition emulsions can not only enhance the patient's immunity, but also act as an antioxidant to prevent the oil and fat therein from deteriorating, thereby improving the overall performance and stability of the enteral nutrition emulsion.

[0063] Test Example 3

[0064] According to GB 15193.1-2014 National Food Safety Standard Food Safety Toxicology Evaluation Procedure, the first phase acute toxicity test and the second phase genetic toxicity test, the traditional teratogenicity test, and the 90-day oral toxicity test of the enteral nutrition emulsion of the present invention were carried out. The results showed that the acute toxicity test results were non-toxic; the bone marrow cell micronucleus test, the mouse sperm teratogenicity test, and the 90-day oral toxicity test were all negative. The toxicology test results provide a basis for the edible safety of the enteral nutrition emulsion of the present invention.

[0065] The preferred specific embodiments of the present invention are described in detail above. It should be understood that a person skilled in the art can make many modifications and changes based on the concept of the present invention without creative work. Therefore, any technical solution that can be obtained by a person skilled in the art through logical analysis, reasoning or limited experiments based on the concept of the present invention on the basis of the prior art should be within the scope of protection determined by the claims.

Claims

1. An enteral nutrition emulsion, It is characterized in that The invention comprises the following components in parts by weight: 13 to 23 parts of soy protein peptide powder, 10 to 20 parts of isolated whey protein powder, 6 to 12 parts of fat, 0.5 to 2 parts of arginine, 3 to 8 parts of lecithin, 12 to 20 parts of dietary fiber, 5 to 10 parts of oligosaccharides, 0.2 to 1 part of minerals, 0.1 to 0.3 parts of vitamins, 0.1 to 0.3 parts of emulsifiers, 0.001 to 0.005 parts of modified astaxanthin and 50 to 80 parts of water.

2. The enteral nutrition emulsion according to claim 1, It is characterized in that The fat is a mixture of sunflower oil, fish oil and rapeseed oil.

3. The enteral nutrition emulsion according to claim 1, It is characterized in that The weight ratio of sunflower oil, fish oil and rapeseed oil in the fat is 30-50:4-6:5-20.

4. The enteral nutrition emulsion according to claim 1, It is characterized in that The minerals are a mixture of calcium carbonate, sodium caseinate, potassium chloride, sodium chloride, ferric pyrophosphate, zinc sulfate, copper sulfate, manganese chloride, sodium molybdate, sodium selenite, potassium iodide, chromium chloride and sodium fluoride.

5. The enteral nutrition emulsion according to claim 1, It is characterized in that In terms of content, the weight ratio of calcium, phosphorus, potassium, sodium, chlorine, iron, zinc, copper, manganese, molybdenum, selenium, iodine, chromium and fluorine in minerals is 40:25:60:25:45:8.5:6.2:45:15:5:15:40:5:0.

35.

6. The enteral nutrition emulsion according to claim 1, It is characterized in that The vitamins are vitamin A, vitamin D, vitamin E, vitamin K 1 , Vitamin B 1 , Vitamin B 2 , Vitamin B 6 , Vitamin B 12 , a mixture of niacin, folic acid, choline and biotin.

7. The enteral nutrition emulsion according to claim 1, It is characterized in that Vitamin A, vitamin D, vitamin E, vitamin K 1 , Vitamin B 1 , Vitamin B 2 , Vitamin B 6 , Vitamin B 12 , niacin, folic acid, choline and biotin have a weight ratio of 450:8:8:50:355:800:450:1.5:300:160:50:

15.

8. The enteral nutrition emulsion according to claim 1, It is characterized in that The preparation method of the modified astaxanthin comprises the following steps: X1. Add vitamin E polyethylene glycol succinate, maleic anhydride and 4-dimethylaminopyridine to dichloromethane, stir for 20-30 hours under nitrogen atmosphere, then add to cold ether. A precipitate will appear. Filter and dialyze with ethanol-water solution for 2-3 days, then dry for the next step. X2. Add astaxanthin to acetone, then add the product of the previous step, 4-dimethylaminopyridine and dicyclohexylcarbodiimide. Stir for 20 to 30 hours under a nitrogen atmosphere and then add to cold ether. A precipitate will appear. Wash it three times and dialyze it for 2 to 3 days to remove impurities to obtain modified astaxanthin.

9. The enteral nutrition emulsion according to claim 8, It is characterized in that The molar ratio of the vitamin E polyethylene glycol succinate to maleic anhydride and 4-dimethylaminopyridine is 1:2-3:1; the molar ratio of astaxanthin to the product of the previous step, 4-dimethylaminopyridine and dicyclohexylcarbodiimide is 1:2-2.5:1-1.5:1-1.

5.

10. A method for preparing the enteral nutrition emulsion according to any one of claims 1 to 9, It is characterized in that The steps include: S1. Add soy protein peptide powder, isolated whey protein powder, arginine, dietary fiber and oligosaccharides into water according to the formula, and mix and stir at 40-55° C. to obtain an aqueous phase; S2, mixing fat and lecithin, stirring evenly to obtain an oil phase; S3. After mixing the water phase, the oil phase and the emulsifier, add the vitamins, minerals and the modified astaxanthin, stir evenly and homogenize, sterilize after filling, and then package.